LaFarge brings a wealth of healthcare innovation and operational leadership experience to MedicaMetrix
BOSTON, MASSACHUSETTS (June 15, 2020) (GLOBE NEWSWIRE) – MedicaMetrix, LLC, a leader in developing and marketing innovative medical devices and healthcare solutions, today announced the appointment of Christopher G. LaFarge as Chief Executive Officer effective June 15, 2020.
Christopher G. LaFarge is an operationally focused director and executive, with extensive experience as a senior executive in closely held companies including entrepreneurial start-ups, high-growth, and mature organizations.
LaFarge has acquired deep experience in the areas of product development, life sciences, QA systems, and financing. LaFarge has provided strategic leadership for early stage, life science, and medical device companies in the fields of urology, anesthesiology, intensive care, and neuroscience as well as companies in the oil and gas, management consulting, and natural resources industries.
LaFarge recently has been the COO of Bach Pharma, a pharmaceutical company developing therapeutics for the treatment of neurodegenerative diseases like ALS and Parkinson’s and other life-threatening illnesses. He is also working with IMARC AI, to develop AI-based decision support for ICU/ER physicians.
In 2004, LaFarge was Founder, President and CEO of the company where he invented ProstaMetric, obtained European regulatory approval (CE Marking certification), created scalable, manufacturing procedures for the device, and developed a quality management system which received ISO13485 certification.
LaFarge has served on the Boards of several privately held corporations, as well as educational and non-profit boards and has an MBA from the Yale School of Management, an MFS in environmental Science from Yale U., and a BA in Biology from Harvard College.
“Christopher brings a wealth of experience as the inventor of ProstaMetrix,” stated Robert Rudelius, President and CEO of MedicaMetrix. “Christopher’s unique history and operational expertise makes him ideally suited to help us solve our manufacturing, quality and logistics challenges as we prepare to bring many new medical devices to life.”
MedicaMetrix develops innovative technologies and device solutions that transform the healthcare status quo, leading to better medical outcomes, streamlined care and enhanced patient experience.
We are leading the development of a new paradigm that transforms the diagnosis, treatment, and management of prostate health by filling the gap between PSA testing and imaging / biopsies. The ProstaMetrix system is a minimally invasive medical device designed to accurately measure the volume of the prostate gland early in the diagnostic process. ProstaMetrix helps physicians assess a patient’s prostate status to better plan and monitor diagnostic procedures, treatments, drug therapies, and guide recommendations for active surveillance versus prostate biopsies.
MedicaMetrix is planning to acquire and develop other new medical devices with the goal to bring them to market rapidly by leveraging our planned production facilities in the U.S. and India.
Cautionary Statements Concerning Forward-Looking Statements
This press release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events, or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements related to the expected impact of COVID-19 on our business, statements regarding our growth, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our assessment of our internal controls over financial reporting, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are and will be subject to risks and uncertainties, which may cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements contained in this press release should be evaluated together with the many uncertainties that affect our business and our market, as well as other risks and cautionary statements set forth in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances, or otherwise.